FI934224L - Substituerade pyrimidiner foer kontroll av komplikationer av diabetes - Google Patents

Substituerade pyrimidiner foer kontroll av komplikationer av diabetes Download PDF

Info

Publication number
FI934224L
FI934224L FI934224A FI934224A FI934224L FI 934224 L FI934224 L FI 934224L FI 934224 A FI934224 A FI 934224A FI 934224 A FI934224 A FI 934224A FI 934224 L FI934224 L FI 934224L
Authority
FI
Finland
Prior art keywords
pyrimidiner
substituerade
foer
complications
diabetes
Prior art date
Application number
FI934224A
Other languages
English (en)
Finnish (fi)
Other versions
FI934224A7 (fi
FI934224A0 (fi
Inventor
Banavara L Mylari
Peter J Oates
Todd W Siegel
William J Zembrowski
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of FI934224A0 publication Critical patent/FI934224A0/fi
Publication of FI934224L publication Critical patent/FI934224L/fi
Publication of FI934224A7 publication Critical patent/FI934224A7/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
FI934224A 1992-09-28 1993-09-27 Substituoituja pyrimidiinejä sokeritaudin lisätautien kontrolliin FI934224A7 (fi)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US95222292A 1992-09-28 1992-09-28

Publications (3)

Publication Number Publication Date
FI934224A0 FI934224A0 (fi) 1993-09-27
FI934224L true FI934224L (fi) 1994-03-29
FI934224A7 FI934224A7 (fi) 1994-03-29

Family

ID=25492671

Family Applications (1)

Application Number Title Priority Date Filing Date
FI934224A FI934224A7 (fi) 1992-09-28 1993-09-27 Substituoituja pyrimidiinejä sokeritaudin lisätautien kontrolliin

Country Status (15)

Country Link
US (2) US5728704A (enExample)
EP (1) EP0662962A1 (enExample)
JP (1) JP2789134B2 (enExample)
KR (1) KR950703539A (enExample)
AU (1) AU683620B2 (enExample)
CA (1) CA2145640C (enExample)
FI (1) FI934224A7 (enExample)
HU (1) HU220669B1 (enExample)
IL (1) IL107085A (enExample)
MY (1) MY115288A (enExample)
NO (1) NO306598B1 (enExample)
NZ (1) NZ254550A (enExample)
TW (1) TW284759B (enExample)
WO (1) WO1994007867A1 (enExample)
ZA (1) ZA937142B (enExample)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994007867A1 (en) * 1992-09-28 1994-04-14 Pfizer Inc. Substituted pyrimidines for control of diabetic complications
DK0640599T3 (da) * 1993-08-26 1998-09-28 Ono Pharmaceutical Co 4-Aminopyrimidin-derivater
GB9325217D0 (en) * 1993-12-09 1994-02-09 Zeneca Ltd Pyrimidine derivatives
ES2174176T3 (es) * 1996-02-29 2002-11-01 Pfizer Procedimiento para reducir el daño en tejido asociado con la isquemia.
EP1402895A1 (en) * 1997-03-07 2004-03-31 Metabasis Therapeutics, Inc. Benzimidazole inhibitors of fructose 1,6-biphosphatase
AU6691798A (en) * 1997-03-07 1998-09-22 Metabasis Therapeutics, Inc. Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase
US6284748B1 (en) 1997-03-07 2001-09-04 Metabasis Therapeutics, Inc. Purine inhibitors of fructose 1,6-bisphosphatase
DE69819311T2 (de) * 1997-03-07 2004-07-29 Metabasis Therapeutics Inc., San Diego Neue benzimidazol inhibitoren der fructose-1,6-bisphosphatase
DE19710435A1 (de) * 1997-03-13 1998-09-17 Hoechst Ag Verwendung von Pyrimidinderivaten zur Prävention von Krebs allein oder in Kombination mit anderen therapeutischen Maßnahmen
AP2003002729A0 (en) * 1997-04-15 2003-06-30 Csir Pharmaceutical compositions having appetite suppressant activity
IL124236A (en) * 1997-05-05 2003-01-12 Pfizer Pharmaceutical composition for treating or reversing diabetic cardiomyopathy comprising aldose reductase inhibitor
RU2327700C2 (ru) * 1998-09-09 2008-06-27 Метабэйзис Терапьютикс, Инк. Новые гетероароматические ингибиторы фруктозо-1,6-бисфосфатазы, содержащие их фармацевтические композиции и способ ингибирования фруктозо-1,6-бисфосфатазы
AU2003242500B2 (en) * 1998-09-09 2006-11-02 Metabasis Therapeutics, Inc. Novel Heteroaromatic Inhibitors of Fructose 1,6-bisphosphatase
DE69910045T2 (de) * 1998-09-09 2004-04-22 Metabasis Therapeutics Inc., San Diego Neue heteroaromatische fructose 1,6-bisphosphatase inhibitoren
US6756360B1 (en) * 1998-12-24 2004-06-29 Metabasis Therapeutics, Inc. Combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes
KR20020005653A (ko) 1999-04-01 2002-01-17 실버스타인 아써 에이. 소르비톨 디하이드로게나제 저해제로서의 아미노피리미딘
DE60009777T2 (de) 1999-04-01 2004-08-19 Pfizer Products Inc., Groton Verbindung für Behandlung und Vorsorge bei Diabetes
GB2355657B (en) * 1999-10-27 2004-07-28 Phytopharm Plc Inhibitors Of Gastric Acid Secretion
US6380200B1 (en) * 1999-12-07 2002-04-30 Pfizer, Inc. Combination of aldose reductase inhibitors and selective serotonin reuptake inhibitors for the treatment of diabetic complications
MXPA02006156A (es) * 1999-12-22 2003-09-22 Metabasis Therapeutics Inc Nuevos profarmacos de bisamidato fosfonato.
AU2001245532B2 (en) * 2000-03-08 2005-08-11 Metabasis Therapeutics, Inc. Novel aryl fructose-1,6-bisphosphatase inhibitors
US7563774B2 (en) * 2000-06-29 2009-07-21 Metabasis Therapeutics, Inc. Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes
GB2363985B (en) 2000-06-30 2004-09-29 Phytopharm Plc Extracts,compounds & pharmaceutical compositions having anti-diabetic activity and their use
JP2004524279A (ja) 2000-11-10 2004-08-12 エフ．ホフマン−ラ　ロシュ　アーゲー ピリミジン誘導体、及びニューロペプチドｙ受容体リガンドとしてのその使用
AP2001002360A0 (en) * 2000-11-30 2001-12-31 Pfizer Prod Inc Combination of gaba agonists and sorbitol dehydrogenase inhibitors.
CA2430309A1 (en) * 2000-11-30 2002-06-06 Pfizer Products Inc. Combination of gaba agonists and aldose reductase inhibitors
US6555573B2 (en) * 2000-12-21 2003-04-29 The Quigley Corporation Method and composition for the topical treatment of diabetic neuropathy
US20040127502A1 (en) * 2001-01-31 2004-07-01 Synaptic Pharmaceutical Corporation Use of GAL3 antagonist for treatment of depression
US7081470B2 (en) * 2001-01-31 2006-07-25 H. Lundbeck A/S Use of GALR3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods
EP1247809A3 (en) * 2001-03-30 2003-12-17 Pfizer Products Inc. Triazine compounds useful as sorbitol dehydrogenase inhibitors
US6825198B2 (en) * 2001-06-21 2004-11-30 Pfizer Inc 5-HT receptor ligands and uses thereof
WO2003033643A2 (en) * 2001-10-15 2003-04-24 Pfizer Products Inc. Three dimensional crystal structure of human sorbitol dehydrogenase and uses thereof
US20030105027A1 (en) * 2001-11-06 2003-06-05 Rosenbloom Richard A. Nutritional supplements and methods for prevention, reduction and treatment of radiation injury
US7435725B2 (en) * 2001-11-06 2008-10-14 The Quigly Corporation Oral compositions and methods for prevention, reduction and treatment of radiation injury
BR0306988A (pt) * 2002-01-18 2004-11-23 Pharmacia Corp Piridazinonas substituìdas como inibidores de p38
KR20040099324A (ko) 2002-03-13 2004-11-26 유로-셀티큐 에스.에이. 아릴 치환된 피리미딘 및 이것의 용도
US7015227B2 (en) * 2002-06-21 2006-03-21 Cgi Pharmaceuticals, Inc. Certain amino-substituted monocycles as kinase modulators
WO2004000820A2 (en) * 2002-06-21 2003-12-31 Cellular Genomics, Inc. Certain aromatic monocycles as kinase modulators
US7083813B2 (en) * 2002-11-06 2006-08-01 The Quigley Corporation Methods for the treatment of peripheral neural and vascular ailments
US7262318B2 (en) * 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
US20050261292A1 (en) * 2004-05-19 2005-11-24 Solvay Pharmaceuticals Gmbh Pharmaceutical composition containing N-sulfamoyl-N'-arylpiperazines for the treatment or inhibition of obesity and related conditions
RU2395503C2 (ru) * 2004-05-19 2010-07-27 Зольвай Фармасьютиклз Гмбх Лекарственные средства, содержащие n-сульфамоил-n'-арилпиперазины, предназначенные для профилактики или лечения ожирения и связанных с ним состояний
US20050288340A1 (en) * 2004-06-29 2005-12-29 Pfizer Inc Substituted heteroaryl- and phenylsulfamoyl compounds
GB0415364D0 (en) 2004-07-09 2004-08-11 Astrazeneca Ab Pyrimidine derivatives
JP2008510018A (ja) * 2004-08-18 2008-04-03 メタバシス・セラピューティクス・インコーポレイテッド フルクトース−１，６−ビスホスファターゼの新規チアゾール阻害物質
AU2005286593A1 (en) * 2004-09-23 2006-03-30 Reddy Us Therapeutics, Inc. Novel pyridine compounds, process for their preparation and compositions containing them
MX2007005137A (es) * 2004-11-23 2007-06-22 Warner Lambert Co Derivados del acido 7-(2h-pyrazol-3-il)-3, 5-dihidroxi-heptanoico como inhibidores de hmg co-a reductasa para el tratamiento de lipidemia.
MX2007007103A (es) * 2004-12-13 2008-03-10 Lilly Co Eli Derivados espiro como inhibidores de lipoxigenasa.
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US7863446B2 (en) * 2006-01-19 2011-01-04 Orchid Research Laboratories Limited Heterocycles
JP5237115B2 (ja) * 2006-01-19 2013-07-17 オーキッド リサーチ ラボラトリーズ リミテッド 新規複素環類
US8158667B2 (en) * 2006-08-21 2012-04-17 Kador Peter F Topical treatment of cataracts in dogs
US8404896B2 (en) 2006-12-01 2013-03-26 Bristol-Myers Squibb Company N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as CETP inhibitors for the treatment of atherosclerosis and cardiovascular diseases
US20090018151A1 (en) * 2007-02-23 2009-01-15 Ezekiel Fink Topical Treatment of Peripheral diabetic complications
JP2010520913A (ja) 2007-03-12 2010-06-17 サズセ アーペーエス ルイボスの抗糖尿病性抽出物
DK2142529T3 (da) * 2007-04-27 2014-02-10 Purdue Pharma Lp Trpv1-antagonister og anvendelser deraf
BRPI0912029A2 (pt) 2008-02-01 2020-06-30 Orchid Research Laboratories Limited novos heterociclos
EP2571860A1 (en) 2010-05-21 2013-03-27 Pfizer Inc 2-phenyl benzoylamides
US8916563B2 (en) 2010-07-16 2014-12-23 The Trustees Of Columbia University In The City Of New York Aldose reductase inhibitors and uses thereof
CA2828343A1 (en) 2011-03-04 2012-09-13 The Scripps Research Institute Edn3-like peptides and uses thereof
SG10201605163PA (en) 2011-06-22 2016-08-30 Purdue Pharma Lp Trpv1 antagonists including dihydroxy substituent and uses thereof
BR112015026513A2 (pt) 2013-04-17 2017-07-25 Pfizer derivados de n-piperidin-3-ilbenzamida para tratar as doenças cardiovasculares
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
EP3352754B1 (en) 2016-06-21 2020-09-02 The Trustees of Columbia University in the City of New York Aldose reductase inhibitors and methods of use thereof
IL272246B2 (en) 2017-07-28 2026-01-01 Applied Therapeutics Inc History of 2-(4-oxo/thioketone/azo-3-((substituted)benzo[d]thiazol-2-yl)methyl)- 3,4-dihydrothieno[3,4-d]pyridazin-1-yl)acetic acid for use as an aldose reductase inhibitor for the treatment of galactosemia or prevention of galactosemia-related complications
CN108101883B (zh) * 2018-01-31 2018-11-13 佳木斯大学附属第一医院 一种用于防治糖尿病视网膜病变的药物及其制备方法
RS66416B1 (sr) 2019-01-18 2025-02-28 Astrazeneca Ab 6'-[[(1s,3s)-3-[[5-(difluorometoksi)-2-pirimidinil]amino]ciklopentil]amino][1(2h),3'-bipiridin]-2-on kao inhibitor pcsk9 i metode njegove primene
KR20220003529A (ko) 2019-04-01 2022-01-10 어플라이드 테라퓨틱스 인크. 알도스 리덕타제의 억제제
MX2021013511A (es) 2019-05-07 2022-02-23 Univ Miami Tratamiento y deteccion de neuropatias heredadas y trastornos asociados.

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1063014A (fr) * 1950-06-14 1954-04-29 Wellcome Found Dérivés de pyrimidine et leur préparation
GB959699A (en) * 1961-06-09 1964-06-03 May & Baker Ltd New pyrimidine derivatives
US4130714A (en) * 1977-05-23 1978-12-19 Pfizer Inc. Hydantoin therapeutic agents
IE47592B1 (en) * 1977-12-29 1984-05-02 Ici Ltd Enzyme inhibitory phthalazin-4-ylacetic acid derivatives, pharmaceutical compositions thereof,and process for their manufacture
FR2489141A1 (fr) * 1980-09-03 1982-03-05 Sevifra Appareil chirurgical pour la decoupe precise de la cornee
DOP1981004033A (es) * 1980-12-23 1990-12-29 Ciba Geigy Ag Procedimiento para proteger plantas de cultivo de la accion fitotoxica de herbicidas.
CA1176269A (en) * 1981-03-02 1984-10-16 Kazimir Sestanj N-naphthoylglycine derivatives
US4864028A (en) * 1983-09-14 1989-09-05 Alcon Laboratories, Inc. Spiro-tricyclicaromatic succinimide derivatives
US5066659A (en) * 1984-10-30 1991-11-19 Pfizer Inc. Spiro-heteroazalones for treatment of diabetic complications
US5102908A (en) * 1985-03-15 1992-04-07 Michael Albeck Method of treating Acquired Immunedeficiency Syndrome (AIDS) using organic tellurium and selenium derivatives
GB8524663D0 (en) * 1985-10-07 1985-11-13 Fujisawa Pharmaceutical Co Quinazoline derivatives
JPH0637473B2 (ja) * 1985-10-11 1994-05-18 三共株式会社 ラクタム化合物
US4939140A (en) * 1985-11-07 1990-07-03 Pfizer Inc. Heterocyclic oxophthalazinyl acetic acids
US4835410A (en) * 1988-02-26 1989-05-30 Black & Decker Inc. Dual-mode corded/cordless system for power-operated devices
GB8810203D0 (en) * 1988-04-29 1988-06-02 Ici Plc Heterocyclic compounds
GB8902405D0 (en) * 1989-02-03 1989-03-22 Ici Plc Heterocyclic compounds
DE3905364A1 (de) * 1989-02-22 1990-08-23 Hoechst Ag Substituierte pyrimidin-derivate, verfahren zu ihrer herstellung und ihre verwendung als tool
US4996204A (en) * 1989-05-11 1991-02-26 Pfizer Inc. Pyrido[2,3-d]pyridazinones as aldose reductase inhibitors
US5039672A (en) * 1990-04-05 1991-08-13 Pfizer Inc. Heterocyclic compounds as aldose reductase inhibitors
US5098904A (en) * 1990-06-27 1992-03-24 Bristol-Myers Squibb Company Cerebral function enhancing pyrimidinyl derivatives
GB9016984D0 (en) * 1990-08-02 1990-09-19 Ici Plc Aniline derivatives
DE4025387A1 (de) * 1990-08-10 1992-02-13 Hoechst Ag Substituierte pyrimidin-derivate, verfahren zu ihrer herstellung und ihre verwendung als reagenzien
WO1992004333A1 (fr) * 1990-08-31 1992-03-19 Nippon Shinyaku Co., Ltd. Derive de pyrimidine et medicament
WO1994007867A1 (en) * 1992-09-28 1994-04-14 Pfizer Inc. Substituted pyrimidines for control of diabetic complications

Also Published As

Publication number Publication date
KR950703539A (ko) 1995-09-20
HUT65531A (en) 1994-06-28
TW284759B (enExample) 1996-09-01
CA2145640C (en) 2001-01-30
JP2789134B2 (ja) 1998-08-20
NO951155D0 (no) 1995-03-27
AU4669793A (en) 1994-04-26
NO306598B1 (no) 1999-11-29
NZ254550A (en) 1997-08-22
EP0662962A1 (en) 1995-07-19
US5728704A (en) 1998-03-17
FI934224A7 (fi) 1994-03-29
JPH07507072A (ja) 1995-08-03
HU220669B1 (hu) 2002-04-29
AU683620B2 (en) 1997-11-20
CA2145640A1 (en) 1994-04-14
ZA937142B (en) 1995-03-23
HU9302734D0 (en) 1993-12-28
US5866578A (en) 1999-02-02
IL107085A (en) 2001-01-11
IL107085A0 (en) 1993-12-28
MY115288A (en) 2003-05-31
FI934224A0 (fi) 1993-09-27
NO951155L (no) 1995-05-26
WO1994007867A1 (en) 1994-04-14

Similar Documents

Publication Publication Date Title
FI934224L (fi) Substituerade pyrimidiner foer kontroll av komplikationer av diabetes
DE69432285D1 (de) Fernbedienung
FI933243L (fi) Foerfarande foer framstaellning av pultruderad panel
AU8985291A (en) Pitch control
ATE137828T1 (de) Pechkontrolle
DE69212721D1 (de) Prozesssteuerung
DE69328938D1 (de) Steuergerät
DE69209443D1 (de) Schaltfeld
DE59307183D1 (de) Steuerschaltung
DE69213564D1 (de) Getriebe-Anfahrsteuerung
DE69311405D1 (de) Blendensteuerung
DE69315318D1 (de) Steuerungseinrichtung
ATA245393A (de) Temperaturregler
DE69127893D1 (de) Zählergesteuerte verschlussregelschaltung
FI931969A0 (fi) Kontrollering av perfusionshastigheter i kontinuerlig bioreaktorodlingav djurceller
DE69305074D1 (de) Temperaturregelung
KR950700179A (ko) 조종 레버(control lever)
DE69314379D1 (de) Steuerschaltung
DE69318777D1 (de) Kontraststeuerschaltung
NO924717D0 (no) Fjernstyring av skilleinnretning
DE59307239D1 (de) Regelungs-anordnung
KR950702094A (ko) 항생제에 의한 조류의 억제 방법(control of angae with antibiotics)
FI923719A0 (fi) Detektering av susceptibilitet foer diabetes.
UA166S (uk) Пульт управління
SE9302451D0 (sv) Styranordning av timertyp

Legal Events

Date Code Title Description
FD Application lapsed